Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.
On April 29, 2026, H.C. Wainwright hiked Relay Therapeutics, Inc. (NASDAQ:RLAY)’ price target from $19 to $25. It also maintained a Buy rating on the stock. The firm noted Phase 1 zovegalisib triplet results that “derisk” the anticipated Phase 3 study.
On May 5, 2026, Relay Therapeutics, Inc. (NASDAQ:RLAY) announced that the FDA had granted Breakthrough Therapy designation to zovegalisib paired with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer, which the Phase 1/2 ReDiscover study findings supported. At ESMO TAT, the company reported 400mg BID doublet results. It showed 11.1 months of median progression-free survival in severely pre-treated patients, with essentially equal efficacy across kinase and non-kinase variants.
For frontline breast cancer, Relay Therapeutics, Inc. (NASDAQ:RLAY) chose zovegalisib plus atirmociclib as the next triplet, with a 44% objective response rate in median third-line patients at unoptimized dosages. A Phase 3 trial aimed at endocrine sensitive patients is planned to begin in early 2027, with Pfizer providing atirmociclib.
Relay Therapeutics, Inc. (NASDAQ:RLAY) ended the first quarter with $642.1 million in cash from $554.5 million at the end of the previous year. It also stated that existing finances would sustain operations through 2029.
Relay Therapeutics, Inc. (NASDAQ:RLAY) is a firm that works to transform the drug discovery process. It focuses on advancing small-molecule therapeutic discovery in targeted oncology.
While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
